Login / Signup

Retrospective analysis of the effectiveness of a reduced dose of idarucizumab in dabigatran reversal.

Louisa StoneEileen MerrimanGordon RoyleMerit HannaHenry S H Chan
Published in: Thrombosis and haemostasis (2021)
An initial 2.5g dose of idarucizumab appears effective for dabigatran reversal in the real-world setting.
Keyphrases
  • atrial fibrillation
  • randomized controlled trial
  • systematic review